Genetic Signatures also reported second quarter sales on par with the prior-year-quarter, reflecting higher respiratory testing in the Australian winter.

The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.

The CEO submitted claims with codes for services that were never performed and received payments from more than one source for the same test.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

Last week, readers were most interested in a story about Waters acquiring BD's biosciences and diagnostics solutions business.

The partners intend to develop a point-of-care testing instrument that can be used to aid the diagnosis of cancers and other diseases.

Oncologists were one of the few provider groups to register support for the FDA rule, reflecting the challenge of assessing ...

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

360Dx regularly updates this tracker to provide readers with accurate information on the regulatory status of these tests in the US, European, and Asian markets.

The firm said that the refinancing agreement provides for a $1.17 billion secured term loan and a $1.25 billion secured revolving credit facility.

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.